Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

U.S. congressional panel, SEC reach deal in insider trading probe

Published 11/14/2016, 07:25 PM
Updated 11/14/2016, 07:30 PM
© Reuters. To match Special Report SEC/INVESTIGATIONS

© Reuters. To match Special Report SEC/INVESTIGATIONS

By Nate Raymond

NEW YORK (Reuters) - A U.S. House of Representatives panel and an ex-staff member have agreed to end a fight over subpoenas the U.S. Securities and Exchange Commission issued during a probe into possible insider trading on leaked information about Medicare reimbursement rates.

In a letter filed on Monday in federal court in Manhattan, lawyers for the SEC, the House Ways and Means Committee and ex-staffer Brian Sutter said they had reached an agreement on a protocol for the agency to review documents it had sought.

The SEC said the congressional panel and Sutter had as a result agreed to dismiss an appeal of a November 2015 ruling by U.S. District Paul Gardephe that had required them to comply with subpoenas issued in the probe.

"The parties are hopeful that their agreement, although presently only a partial resolution of the referenced proceeding, may culminate in a full resolution of it," the letter said.

Representatives for the committee, the SEC and Sutter did not immediately respond to a request for comment.

The decision to drop the appeal came after a three-judge panel of the 2nd U.S. Circuit Court of Appeals in June appeared during oral arguments to lean in favor of forcing Congress to comply at least somewhat with two SEC subpoenas.

The case was seen as a test of how far securities enforcers may go to police the murky world of "political intelligence," in which firms seek to gather and sell information for traders.

According to court filings, the SEC has been looking into an email a lobbyist at the law firm Greenberg Traurig LLP sent to an analyst at broker-dealer Height Securities regarding a deal struck in Congress about Medicare reimbursement rates in 2013.

The SEC said the email was sent before the Centers for Medicare and Medicaid Services announced the rates after U.S. markets closed and about 30 minutes before Height issued a report suggesting the change could help companies such as Humana Inc (N:HUM).

The SEC's probe came to focus in part on Sutter, who the regulator said on the day of the announcement had spoken with the Greenberg Traurig lobbyist and had discussed the rate announcement on that call.

Federal prosecutors in Manhattan had also launched an investigation related to the alleged leak, according to congressional records. The status of that probe was unclear on Monday.

© Reuters. To match Special Report SEC/INVESTIGATIONS

The case is SEC v. Committee on Ways and Means of the U.S. House of Representatives et al, U.S. District Court, Southern District of New York, No. 14-mc-00193.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.